It is a broadly described annual report of The IBN SINA Pharmaceutical Industry Limited in the year of 2010. In 2010 company’s EPS stood at Tk. 55.62 which was Tk. 45.59 (adjusted) in 2009. In the year the company’s net asset value per share was Tk. 248.83 which was Tk. 239.34 in 2009. Total Net Asset Value (NAV) in 2010 was Tk. 268,731,129 while in the previous year it was Tk. 215,410,234. Net Operating Cash flow per share (NOCFPS) was Tk. 131.13 as against Tk. 76.96 in the previous year. In the year 2010 overall sales achievement stood at Tk. 1605.17 million which was Tk.1277.87 million in the last year. The total growth rate was 25.61%. The growth rate of pharma sales was 23.48% and natural medicine was 46.20%. During the year the company earned foreign exchange of US $ 138,922 and Euro € 17,161.07 equivalent to Tk.11.197,217 on account of export sale but did not earn or receive any income in respect of royalty, technical know-how, professional & advisory fees, interest & dividend.
After evaluating the financial accounts of the company in the year 2010, the Board of Directors proposed a stock dividend of 20% and a cash dividend of 10% per share of Tk. 100.
More Annual Report of The IBN SINA Pharmaceutical Industry Limited:
- Annual Report 2010 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2011 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2012 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2013 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2014 of The IBN SINA Pharmaceutical Industry Limited
- Annual Report 2017 of The IBN SINA Pharmaceutical Industry Limited
